GM-CSF drug trial for mild to moderate Alzheimer’s disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 60 to 85 years old when you sign consent.
- You have a dedicated caregiver/partner who spends at least 12 hours per week with you, can join study visits, and can answer questions about your thinking, daily function, and behavior.
- You can do study check-ins that involve seeing and hearing clearly, plus reading/writing tasks for memory and thinking tests.
- Your Alzheimer’s diagnosis is mild or moderate (or research-probable similar), and your MoCA score is 4 to 24 at screening.
- Your Alzheimer’s brain amyloid is confirmed by blood and either CSF testing or an amyloid PET scan.
- You must live close enough to the study site to reliably attend visits, including nearby lab blood draws.
- If taking common Alzheimer’s medicines (like donepezil, rivastigmine, galantamine, or memantine), your dose must be stable for at least 60 days before screening, and your other medications stable for at least 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell treatment (called RB-ADSCs) that is injected into the fluid around your brain. It aims to see if these cells can help slow down memory loss and thinking problems in people with mild to moderate Alzheimer's disease.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.